On October 13, AKESO fell 3.45% in regular trading, trading at HK$103.8 with turnover of HK$104 million. The decline follows a sector-wide pullback in Hong Kong biotech stocks, with the Hang Seng Biotech Index having dropped more than 3% in a prior session, reflecting weakening industry sentiment and short-term profit-taking pressure after recent sharp gains.
Background shows AKESO had surged over 15% in late September after AstraZeneca announced a US$2 billion strategic investment in Summit Therapeutics, AKESO's partner for ivonescimab, a PD-1/VEGF bispecific antibody. The rally was further supported by positive overall survival data from the HARMONi-2 study presented at the World Conference on Lung Cancer, where ivonescimab demonstrated superiority over pembrolizumab. In addition, the company reported first-half revenue of RMB 1.806 billion, up 27.92% year-over-year, with net loss narrowing to RMB 447 million from RMB 588 million a year earlier. Despite these positive catalysts, the current movement reflects broader sector weakness and consolidation after the stock's sharp advance.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments